Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 28, 2018 10:04:03 GMT -5
In person recap: * Yesterday’s investors conference was an intimate group of about 3 dozen people attending in person, with hundreds more listening online * The management team did a great job with their presentations. The scientific presentations by Edelman and Kendall were very comprehensive. I was hoping Mike’s company overview presentation was more exciting * Mike Castagna and David Kendall was present in person. This team has had a long week having just finished the ADA Conference this weekend. Edelman attended the ADA in person but participated digitally at yesterday’s investors conference * After I picked up my name tag, Mike Castagna was right there to shake my hand and welcome me into the conference room. I was star struck * There was no seating chart but I found myself sitting at a table with Ilya Kravets from HC. Wainwright, two people from MSQ Ventures (focused on partnering U.S. based technology, consumer, and healthcare companies with strategic Chinese corporate and institutional investors) and one person from Jeffries. There was really no time to chatter as the presentation started immediately * FDA approved drugs have not moved the needle in taking care of diabetics for the past decade! There has been substantial advances but true innovation has been lacking. CGM + Afrezza will change that! * Dr. Edelman believes the key to Afrezza being successful is adherence and persistence * Kendall and Steve are friends. Kendall was a student of Steven Edelman * Mike and Kendall are a one-two punch! The remainder of the year will be fun to watch as the team continues to present the results of past studies, both at upcoming national and international conferences notice other companies there in addition to Jeffries? Roth |
|
|
|
Post by peppy on Jun 28, 2018 10:04:58 GMT -5
Thank you Kite for report!.
Another Dr. Kendall fun fact.
If your blood glucose level is 30 mg/dl lower on average throughout the day, HbA1c will be lowered by 1% point.
|
|
|
|
Post by goyocafe on Jun 28, 2018 10:19:38 GMT -5
I also question why Dr. E just uses Afrezza on a limited basis. Why doesn’t he dump the pump? Sayhey has indicated that Dr. E is in an awkward position because he takes Afrezza himself, but he is a doctor that teaches patients to use a pump. Once you have a business built, it is hard to accept that it is built on sand. Even though Dr. E. knows the truth, it is unfortunately human nature that he will try to milk out his paychecks based on the highly-acclaimed experience and professional stature he has acquired as a pump advocate. My guess is that he will eventually change his tune. And, hey Sports, yet again you have a very good point. Pushing Afrezza even just for corrections would be a great stepping stone. The more PWDs use it, and the more good info that Dr. K drives to the market, and the more insurance improves, the more PWDs will start increasing their dosing until they get to the point where they decide to dump the pump. Dr. E could move his business towards VDEX and do quite well. |
|
|
|
Post by stockwhisperer on Jun 28, 2018 10:29:49 GMT -5
I also question why Dr. E just uses Afrezza on a limited basis. Why doesn’t he dump the pump? Sayhey has indicated that Dr. E is in an awkward position because he takes Afrezza himself, but he is a doctor that teaches patients to use a pump. Once you have a business built, it is hard to accept that it is built on sand. Even though Dr. E. knows the truth, it is unfortunately human nature that he will try to milk out his paychecks based on the highly-acclaimed experience and professional stature he has acquired as a pump advocate. My guess is that he will eventually change his tune. And, hey Sports, yet again you have a very good point. Pushing Afrezza even just for corrections would be a great stepping stone. The more PWDs use it, and the more good info that Dr. K drives to the market, and the more insurance improves, the more PWDs will start increasing their dosing until they get to the point where they decide to dump the pump. Did not get the impression from the meeting that the pump is frequently used but maybe misunderstood that. Thanks |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 28, 2018 10:36:33 GMT -5
We were just talking about Dr. E. continuing to use a pump and teaching his patients to use it, even though he believes in Afrezza.
Oh, I think I confused things in my last sentence when I threw in the "dump the pump" thing again. The stepping stone analogy does not apply to just pump-users. I was really referring to the general (large) pool of PWD that could use Afrezza as a stepping stone ... not just pump users. I should have said that PWDs can use Afrezza for corrections at first, then increase until they use it for all their bolus needs.
|
|
|
|
Post by agedhippie on Jun 28, 2018 10:40:44 GMT -5
Sayhey has indicated that Dr. E is in an awkward position because he takes Afrezza himself, but he is a doctor that teaches patients to use a pump. Once you have a business built, it is hard to accept that it is built on sand. Even though Dr. E. knows the truth, it is unfortunately human nature that he will try to milk out his paychecks based on the highly-acclaimed experience and professional stature he has acquired as a pump advocate. My guess is that he will eventually change his tune. And, hey Sports, yet again you have a very good point. Pushing Afrezza even just for corrections would be a great stepping stone. The more PWDs use it, and the more good info that Dr. K drives to the market, and the more insurance improves, the more PWDs will start increasing their dosing until they get to the point where they decide to dump the pump. Did not get the impression from the meeting that the pump is frequently used but maybe misunderstood that. Thanks You misunderstood. He uses the pump for basal, and for mealtime insulin except if he is eating fast carbs. He uses Afrezza for food with fast carbs, and for corrections. It's all in the call. |
|
|
|
Post by sportsrancho on Jun 28, 2018 11:04:16 GMT -5
In person recap: * Yesterday’s investors conference was an intimate group of about 3 dozen people attending in person, with hundreds more listening online * The management team did a great job with their presentations. The scientific presentations by Edelman and Kendall were very comprehensive. I was hoping Mike’s company overview presentation was more exciting * Mike Castagna and David Kendall was present in person. This team has had a long week having just finished the ADA Conference this weekend. Edelman attended the ADA in person but participated digitally at yesterday’s investors conference * After I picked up my name tag, Mike Castagna was right there to shake my hand and welcome me into the conference room. I was star struck * There was no seating chart but I found myself sitting at a table with Ilya Kravets from HC. Wainwright, two people from MSQ Ventures (focused on partnering U.S. based technology, consumer, and healthcare companies with strategic Chinese corporate and institutional investors) and one person from Jeffries. There was really no time to chatter as the presentation started immediately * FDA approved drugs have not moved the needle in taking care of diabetics for the past decade! There has been substantial advances but true innovation has been lacking. CGM + Afrezza will change that! * Dr. Edelman believes the key to Afrezza being successful is adherence and persistence * Kendall and Steve are friends. Kendall was a student of Steven Edelman * Mike and Kendall are a one-two punch! The remainder of the year will be fun to watch as the team continues to present the results of past studies, both at upcoming national and international conferences Thanks so much, great recap! I’m so glad you were there, and glad you were starstruck ..pretty fun huh:-) |
|
|
|
Post by stockwhisperer on Jun 28, 2018 11:04:27 GMT -5
Did not get the impression from the meeting that the pump is frequently used but maybe misunderstood that. Thanks You misunderstood. He uses the pump for basal, and for mealtime insulin except if he is eating fast carbs. He uses Afrezza for food with fast carbs, and for corrections. It's all in the call. Sorry, I was referring to what I thought was said about Type 1 & that the pump was not largely used, not his individual use of it. |
|
|
|
Post by oldfishtowner on Jun 28, 2018 11:05:59 GMT -5
Thank you Kite for report!. Another Dr. Kendall fun fact. If your blood glucose level is 30 mg/dl lower on average throughout the day, HbA1c will be lowered by 1% point. Actually, you said it first, peppy, in the HbA1c conversion chart you posted on the ADA thread. |
|
|
|
Post by mnholdem on Jun 28, 2018 11:09:40 GMT -5
* Dr. Edelman believes the key to Afrezza being successful is adherence and persistence
Perhaps one of the reasons that Edelman is an insulin pump advocate is because he recognizes that it's more likely that patients will adhere to their treatments with a pump that with other manually-administered treatments. The pump is simple, although some can be a bit much for the technically-challenged, especially for calibrating and maintenance.
Where Afrezza shines is that it's simple to use, even though it's not automated. One of the challenges facing Castagna and Kendall resides in communicating the simplicity of Technosphere Insulin to the diabetes treatment community. So many endos are concerned with 1-unit increments, and rightly so, because RAA's have such a long tail. How much RAA insulin is still in your bloodstream from dosing your last meal? It's complicated and, frankly, doctors have gotten accustomed to insulin being complicated, especially if self-dosed without a pump.
Afrezza doesn't have that long tail. It's out of the bloodstream before the next meal, so complicated calculations that take insulin stacking into account with Novolog and Humalog have become a thing of the past with Afrezza. The real challenge is to get that message out in a manner in which it can be understood and accepted.
Once that's done (and it will take a monumental effort by Dr. Kendall) then wide-scale adoption will naturally follow.
|
|
|
|
Post by babaoriley on Jun 28, 2018 11:15:17 GMT -5
Exactly, which is part of the reason the stock didn't do much of anything. Perhaps what everyone knows here. But not everybody in the world knows this. Stock price is being controlled by a hedgefund trying to kill mnkd right now before it steals market share from their big bipharma customer. Steve, yes, exactly, it's what everyone here knows, in broad concepts compared to the great detail of yesterday's presentation. And not everybody in the world knows this - that's for darn sure, and yesterday did not do much to change that; those of us who listened are already disciples - hopefully some of whom listened in person will become disciples as well. |
|
|
|
Post by babaoriley on Jun 28, 2018 11:19:35 GMT -5
Sports, is that your First Communion or your Confirmation picture?  |
|
|
|
Post by cjc04 on Jun 28, 2018 11:34:17 GMT -5
* Dr. Edelman believes the key to Afrezza being successful is adherence and persistence
Perhaps one of the reasons that Edelman is an insulin pump advocate is because he recognizes that it's more likely that patients will adhere to their treatments with a pump that with other manually-administered treatments. The pump is simple, although some can be a bit much for the technically-challenged, especially for calibrating and maintenance.
Where Afrezza shines is that it's simple to use, even though it's not automated. One of the challenges facing Castagna and Kendall resides in communicating the simplicity of Technosphere Insulin to the diabetes treatment community. So many endos are concerned with 1-unit increments, and rightly so, because RAA's have such a long tail. How much RAA insulin is still in your bloodstream from dosing your last meal? It's complicated and, frankly, doctors have gotten accustomed to insulin being complicated, especially if self-dosed without a pump.
Afrezza doesn't have that long tail. It's out of the bloodstream before the next meal, so complicated calculations that take insulin stacking into account with Novolog and Humalog have become a thing of the past with Afrezza. The real challenge is to get that message out in a manner in which it can be understood and accepted.
Once that's done (and it will take a monumental effort by Dr. Kendall) then wide-scale adoption will naturally follow.
I agree, once it’s understood how Afrezza works, and that it’s the #1 solution to the problem, then there’ll be no looking back.... Unfortunately they, the diabetes community of care givers, is still not even aware of the PROBLEM that Afrezza magically solves. “They” still follow the holy grail of the A1c and if it’s close to 7 then you're fine, with no understanding of how much time someone is OUT of range if they’re at 7. IMO,,,, the PROBLEM needs to be the headline everywhere!!! IF YOU'RE AT 6.5 AND HAVING HYPO’s AT NIGHT, THEN YOU’RE NOT FINE, YOU’RE SICK, AND YOU’RE HAVING HYPER’s THAT ARE SLOWLY KILLING YOUR ORGANS. YOUR DOC IS NOT HELPING YOU!!!!! |
|
|
|
Post by cjc04 on Jun 28, 2018 11:37:34 GMT -5
Any chance that yesterday gets MNKD a new debt deal instead of an offering of shares? Just thinking about how awesome THAT would be if it were announced.
|
|
|
|
Post by hammer on Jun 28, 2018 12:42:26 GMT -5
I finally had the chance to listen to the presentation. I wish Edelman was personally there to give his presentation. I thought his presentation was slightly better than Kendalls.
I actually thought all three presenters did a great job. The mere fact Mannkind has drawn the attention of Kendell and Edelman speaks volumes! I cannot stress that enough, they are heavyweights! I would offer one suggestion to Castagna for the recruitment of the endo from Wash U who sat on the adcom panel. Her name escapes me but every medical intern walks around with the Washington Manuel of Medical Therapeutics in their lab coat side pocket. She was supportive of Afrezza at adcom and could be influential in new physician training. They need to hit new physicians during training is as important to gain pediatric approval. I have written previously about interaction with 2 new resident physicians who never heard of Afrezza.
Anyway my take-a-ways are such:
Time in range will soon be standard of care as evidenced and pushed by CGM
The pump is all but dead.
Phase 1 insulin effect is extremely important and Afrezza is superior in regard. I have not heard to much of this since the days of Al Mann.
Afrezza is the only prandial insulin when used in conjunction with CGM that can be viewed in real time versus through the rear view mirror with injectables. This was displayed but not driven home as well as it should.
The unique synergistic use of Afrezza and CGM has caused alot of interest from CGM manufacturers and likewise with MNKD. This gets back to the previous point that its the only prandial insulin that actually compliments the use and need of CGM.
Over the last 20 years oral antidiabetic therapy has not decreased overall A1C. One has to wonder is the risk outweigh the benefits.
The greatest current innovation has been in the realm of CGM. Once again Afrezza fits the challenge.
So for years many of us have been looking toward partner or BO by BP. My current thinking looks to co-promotion with CGM makers, at least in the short term since it could be a source of revenue to continue efforts. As long as the movement is toward TIR and CGM as standard of care. Afrezza will be the standard for the next 15-20 years. The institutional investor conference was the "Can You Hear Me know Moment"! GLTA
|
|
